WO2011025271A3 - Metformin ascorbate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same - Google Patents

Metformin ascorbate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same Download PDF

Info

Publication number
WO2011025271A3
WO2011025271A3 PCT/KR2010/005714 KR2010005714W WO2011025271A3 WO 2011025271 A3 WO2011025271 A3 WO 2011025271A3 KR 2010005714 W KR2010005714 W KR 2010005714W WO 2011025271 A3 WO2011025271 A3 WO 2011025271A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
metformin
ascorbate
pharmaceutical composition
combined formulation
Prior art date
Application number
PCT/KR2010/005714
Other languages
French (fr)
Korean (ko)
Other versions
WO2011025271A2 (en
Inventor
김성욱
전성수
민창희
구자성
강민석
김용은
Original Assignee
한올바이오파마주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올바이오파마주식회사 filed Critical 한올바이오파마주식회사
Publication of WO2011025271A2 publication Critical patent/WO2011025271A2/en
Publication of WO2011025271A3 publication Critical patent/WO2011025271A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to metformin ascorbate, to a method for preparing same, to a pharmaceutical composition comprising same, and to a combined formulation comprising same. The metformin ascorbate of the present invention has superior stability, enables easy tabletting, and has low toxicity, and thus can be effectively used in treating glycosuria, diabetes, metabolic syndrome, diabetes complications, menstrual irregularities, hypertension, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, cancer, myalgia, symptoms of muscle cell cytotoxicity, rhabdomyolysis, climacterium, etc., and/or provides antioxidant activity.
PCT/KR2010/005714 2009-08-25 2010-08-25 Metformin ascorbate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same WO2011025271A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090078551 2009-08-25
KR10-2009-0078551 2009-08-25

Publications (2)

Publication Number Publication Date
WO2011025271A2 WO2011025271A2 (en) 2011-03-03
WO2011025271A3 true WO2011025271A3 (en) 2011-07-14

Family

ID=43628605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005714 WO2011025271A2 (en) 2009-08-25 2010-08-25 Metformin ascorbate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same

Country Status (2)

Country Link
KR (1) KR101211227B1 (en)
WO (1) WO2011025271A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (en) 2005-02-03 2011-10-31 Wyeth Llc Method for treating gefitinib resistant cancer
PE20070763A1 (en) 2005-11-04 2007-08-08 Wyeth Corp ANTINEOPLASTIC COMBINATIONS OF AN INHIBITOR OF mTOR, TRASTUZUMAB AND / OR HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (en) 2008-06-17 2012-08-22 惠氏有限责任公司 Antineoplastic combinations containing HKI-272 and vinorelbine
CN102202667A (en) 2008-08-04 2011-09-28 惠氏有限责任公司 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
MX356593B (en) 2009-04-06 2018-06-05 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer.
WO2011056741A2 (en) 2009-11-09 2011-05-12 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2014181968A1 (en) * 2013-05-09 2014-11-13 가톨릭대학교 산학협력단 Composition for preventing or treating immune diseases, containing metformin and coenzyme q10 as active ingredients
CN112716949A (en) * 2021-02-03 2021-04-30 天津科技大学 Antineoplastic drug composition, preparation and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796551A1 (en) * 1999-07-23 2001-01-26 Lipha New metformin salts, e.g. the thioctate, hippurate or alginate, having improved passage through the digestive barrier and improved resorption, useful for treating diabetes
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796551A1 (en) * 1999-07-23 2001-01-26 Lipha New metformin salts, e.g. the thioctate, hippurate or alginate, having improved passage through the digestive barrier and improved resorption, useful for treating diabetes
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin

Also Published As

Publication number Publication date
KR101211227B1 (en) 2012-12-11
WO2011025271A2 (en) 2011-03-03
KR20110021693A (en) 2011-03-04

Similar Documents

Publication Publication Date Title
WO2011025271A3 (en) Metformin ascorbate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2011025269A3 (en) Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2011025267A3 (en) Metformin methanesulfonate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2011025270A3 (en) Metformin caffeic acid salt, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
NZ597193A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2008006715A3 (en) Improvements relating to pharmaceutical compositions
AR058098A1 (en) DERIVATIVES OF DICARBOXYL ACIDS AND THEIR USE
WO2007127726A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127688A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
GEP20104994B (en) Tetrahydroindolone and tetrahydroindazolone derivatives
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2008052044A3 (en) Use of derivatives of propofol for treating diseases associated with oxidative stress
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
MX2010002675A (en) Prodrugs to thyroid hormone analogs.
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2006020358A3 (en) Novel biphenyl compounds and their use
MX2012002876A (en) Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof.
HK1099032A1 (en) Esters of hyaluronic acid with rhein, process for their preparation and compositions comprising the same
WO2007031883A3 (en) Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof
GT200500266A (en) NEW DERIVATIVES OF PYRIMIDINE AND ITS USE
WO2013022279A3 (en) N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
UA96618C2 (en) 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
WO2005112914A3 (en) Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812284

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812284

Country of ref document: EP

Kind code of ref document: A2